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Abstract The high throughput screening of a library of over 87,000 drug-like compounds against the African Sleeping 
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Trypanosoma brucei gambiense and T. brucei rhodesiense are 
the causative agents of human African trypanosomiasis (HAT), also 
known as sleeping sickness. T. b. rhodesiense is found in Eastern 
and Southern Africa, whereas T. b. gambiense occurs in Western 
and Central Africa and is responsible for over 90% of all reported 
cases of infection.1 This disease threatens about 70 million people 
living in sub-Saharan Africa and causes an estimated 25,000 deaths 
per year.2,3 It has a major impact on the affected nations causing 
suffering and poverty and if left untreated, the disease is usually 
fatal.4 A lack of full-scale screening programs and poor diagnostic 
tools leads to an under-reporting of cases, which is likely to be at 
least threefold higher than the measured value.5  
Both subspecies are transmitted by the bite of the infected tsetse 
fly. T. b. gambiense HAT is primarily a chronic disease and it can 
be many months to years before patients succumb to the disease. In 
contrast, T. b. rhodesiense HAT is acute, with death occurring 
within months of infection. After the bite, the parasites start to 
multiply in the blood; that is, phase I. During this phase, the 
parasite lives within the bloodstream and subsequently migrates to 
other areas of the human body, such as the lymph nodes and spleen, 
causing febrile illness with symptoms similar to those caused by 
malaria (rash, fever, shaking chills, body aches, and general 
fatigue). If phase I is left untreated, the parasites penetrate the 
blood brain barrier and invade the central nervous system (CNS) 
(phase II) causing neurological symptoms including progressive 
mental deterioration, sleep disturbances, long lasting coma and 
finally death if not treated.6 
Unfortunately, vaccines are not available and therefore, the main 
line of defense against the parasite is chemotherapeutics. The 
treatment options are limited with only four registered drugs 
available. Suramin and pentamidine are effective against early 
stage infections while melarsoprol (contains arsenic) and 
eflornithine are used to treat late-stage disease (Figure 1).7,8 These 
drugs were developed approximately 30 years ago and suffer high 
toxicity, lack of efficacy and emerging resistance is a concern. 
Melarsoprol is the most toxic, causing a reactive encephalopathy in 
5−10% of treated patients, with a 1−5% mortality rate.9  
 
Figure 1. Older generation African sleeping sickness drugs. 
Recently, there has been some progress in the treatment of 
HAT10 with a nifurtimox–eflornithine (Figure 1) combination 
(NECT) therapy developed which is as effective as eflornithine 
mono-therapy but was easier and cheaper to administer.11,12 
However, NECT is not ideal due to the parental mode of 
administration, the need to hospitalize patients during treatment and 
the possible development of resistance. 13,14 
Increased research and investment into HAT chemotherapy has 
resulted in the identification of numerous trypanocidal compounds, 
a number of which have entered or are in clinical development. The 
diminazene, pafuramidine15 (Figure 2) was the first oral drug to 
enter clinical development for early stage HAT in 2005. However, 
the observation of severe hepatic toxicity and renal insufficiency 
during a retrospective phase I trial in 2008 lead to the compound 
being abandoned. In 2009, a second orally available drug, 
fexinidazole16 (Figure 2), entered phase I clinical trials for HAT. 
The drug is effective against both stages of the disease and 
subsequently progressed to phase II/III clinical development in 
2012.  
More recently, the novel boron-containing molecule (SCYx-
7158) (Figure 2) emerged as an orally active drug candidate, with 
promising activity against both acute and CNS stage infections. The 
compound successfully completed preclinical studies in 2011 and 
entered phase I clinical trials in 2012.17 The mechanism by which 
the boronate acts as a trypanocidal agent is still unknown. Overall, 
present treatment options for HAT are limited and the high attrition 
rates in drug discovery means that new therapeutics with acceptable 
efficacies and safety profiles are urgently needed.18 
 
Figure 2. New generation of potential African sleeping sickness 
treatments. 
High throughput screening (HTS) is one approach that can be 
used to identify new lead compounds for such neglected diseases. 
Therefore, the HTS library of 87,926 compounds (WEHI 2003)19 
was tested against the non-human infective trypanosome 
subspecies, Trypanosoma brucei brucei and against a mammalian 
cell line HEK293, to determine a selectivity index (SI) for each 
compound. Although T. b. brucei is non-human infective it is 
frequently used in HAT drug discovery campaigns and lead 
optimization programs as a model for the human infective 
subspecies (T. b. gambiense and T. b. rhodesiense) which are more 
difficult to maintain and culture in-vitro. Cluster analysis, 
considering chemical alerts such as toxicophores, the likelihood of 
CNS penetration, and drug-like structural features yielded a subset 
of twelve compounds as promising medicinal chemistry starting 
points for drug development.  
This article discusses the synthesis and anti-trypanocidal activity 
of new analogues for the bis-sulfonamide hit, WEHI-1203255 
(Figure 3), which showed an IC50 value of 1.3 µM with a SI of >32. 
This compound has excellent physiochemical properties, good 
calculated aqueous solubility of 100 µM, an acceptable polar 
surface area of 84 Å2, and an acceptable CLogP value20 of 2.5. The 
analogues were synthesized and tested for their ability to inhibit the 
growth of T. b. brucei limiting the changes to the two sulfonamide 
moieties to study the preliminary structure activity relationships. 
The cytotoxicity profiles of the compounds were evaluated using 
HEK293 cell line and SI was estimated for each analogue. The SI 
of the compounds was determined where possible by directly 
comparing the IC50 values from the T. b. brucei and HEK 293 
assay. If this was not possible, an estimated SI value was calculated 
by comparing the IC50 in the T. b. brucei assay and the highest dose 
at which there was no activity (<50%) in the HEK 293 assay.  
 
Figure 3. Lead compound (WEHI 1203255), IC50= 1.3 µM. 
The strategy for the synthesis of sulfonamide analogues is 
summarised in Scheme 1, and started from 7-
nitrotetrahydroquinoline which was sulfonated using the 
appropriate sulfonyl chloride in pyridine at room temperature. The 
nitro group was reduced, initially using acetic acid in ethanol in the 
presence of tin with sonication,21 however, under these conditions, 
yields were between 50-60%. The use of Raney nickel in methanol 
in presence of hydrazine hydrate as a source of hydrogen reliably 
gave the aniline derivatives in gram quantities in 80-90% yields. 
The amino group was then reacted with the different sulfonyl 
chlorides in pyridine at room temperature (scheme 1), giving in 70-
80% yield, the final analogues. HPLC analysis of these bis-
sulfonamides showed a purity range > 95% for all the synthesized 
derivatives. This facile three step synthetic strategy enabled us to 
access 26 separate derivatives in a short timeframe, reliable yields 
as well and at reasonable cost. 
 
Scheme 1. Reagents and conditions: (a) Dry pyridine, R1SO2Cl, 
rt, 24 h; (b) Methanol, NH2NH2.H2O, Raney Nickel, reflux, 6-8 
h; (c) Dry pyridine, R2SO2Cl, 0 °C to rt, 4-6 h. 
The results for the testing against T. b. brucei, the calculated 
ClogP and the SI are listed in Table 1. The initial activity was 
determined by screening at 1 µM and 10 µM and derivatives 
showing > 80% activity at 10 µM and >50% activity at 1 µM were 
then tested to obtain the IC50 values. The first series of derivatives 
examined the changes in the aromatic sulfonyl moiety where the 
lead compound 10 has a fluorine atom in the ortho position. This 
lead compound was also resynthesised and tested with IC50/SI= 1.3 
µM/>32, confirming the activity results from the initial HTS. 
Changing the ortho-fluoro substituent to the para (11) and meta 
(12) positions, did not improve activity where the IC50/SI profile 
was 7.8 µM/>10 for both derivatives, indicating a slightly 
decreased trypanocidal activity and increased toxicity compared to 
10. Increasing the number of the fluorine atoms had a negative 
effect on the activity, where the addition of a second fluoro 
substituent into the adjacent ortho position (13) resulted in a 
decreased activity (82% activity at 10 µM) as did the presence of 
five fluoro substituents (14, 94% activity at 10 µM). This implied 
the importance of the mono-fluoro atom only in the ortho position, 
with no advantages with the presence of the extra fluorine atoms. 
Table 1 R1, R2, molecular weight, ClogP, IC50 and Selectivity Index for compounds 10-35. 
 R1 R2 Mwt ClogP* IC50 (µM) S.I. 
10 Et 
 
398.5 2.5±0.8 1.3±0.6 32±3.1 
11 Et 
 
398.5 3.0±0.8 7.8±2.7 11.8±4.1 
12 Et 
 
398.5 3.1±0.8 7.8±2.2 11.2±2.5 
13 Et 
 
416.5 2.3±0.9 82% @ 10 µM 
14 Et 
 
470.4 3.4±1.1 94% @ 10 µM 
15 Et 
 
477.4 3.5±0.9 9.9±3.3 9.0±2.3 
16 Et 
 
386.5 2.3±0.8 4.0±0.6 20.8±2.9 
17 Et 
 
465.4 3.5±0.9 11.2±2.6 7.7±1.6 
18 Et 
 
421.0 3.3±0.9 13.1±4.3 6.9±2.2 
19 Et 
 
394.5 3.1±0.8 3.4±0.9 25.8±2.9 
20 Et Et 332.4 1.6±0.8 14% @ 10 µM 
21 Et 
 
386.4 2.8±0.9 18% @ 10 µM 
22 Pr 
 
408.5 3.7±0.8 
1.84 ± 
0.09 
29 ± 
25.4 
23 Pr 
 
436.6 4.5±0.8 
1.71 ± 
0.53 
8.9 ± 1.5 
24 Pr 
 
470.6 4.9±0.8 5.7 ± 2.8 
16.6 ± 
8.2 
25 Pr 
 
412.5 3.0±0.8 3.5 ±0.8 
24.3 ± 
5.3 
26 Pr 
 
400.5 2.8±0.8 < 10% @ 10 µM 
27 Pr 
 
408.5 3.7±0.8 11% @ 10 µM 
28 Pr 
 
408.5 3.7±0.8 <10% @ 10 µM 
29 Pr 
 
422.6 4.1±0.8 9 ± 4.3 10.4 ± 5 
30 Pr 
 
422.6 4.1±0.8 <10% @ 10 µM 
31 Pr 
 
464.6 5.5±0.8 7.9 ±3.2 11.4±4.7 
32 
  
440.6 2.3±0.8 35% 10 µM 
33 
 
 
448.6 3.1±0.8 3.1±0.9 2.5±0.5 
34 
 
 
448.6 3.1±0.8 7.6±2.6 1.7±0.5 
35 
  
456.6 3.9±0.8 3.9±0.9 1.8±0.4 
*Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, 
Canada), S.I. = selectivity index. 
The fluorine atom is the smallest halogen size, therefore, it 
was interesting to test the presence of other halogen atoms. 
The addition of a bromo substituent at the para position 
(compound 15) resulted in increased toxicity and did not 
improve the activity (IC50/SI= 9.9 µM/>8).  
Replacing the benzene moiety with its bioisostere 
thiophene22,23 (16) resulted in a similar activity (IC50/SI= 4.0 
µM/>20) compared to the lead 10. The same activity profile of 
10 and the simpler 16 might be attributed to the lipophilic 
nature of the thiophene ring in 16 that might have the same 
effect as the fluorine atom in 10. The addition of another 
halogen to this thiophene (Br, 17) showed a decreased 
trypanocidal activity (IC50/SI= 11.2 µM/>7), and a concurrent 
reduction in the SI value compared to the unsubstituted 
thiophene analogue 16. Replacement of the bulky bromo 
substituent in 17 by a chloro substituent (18) was also not 
tolerated, with a similar decrease in activity (IC50/SI= 13.1 
µM/>6). The activity of 18 was 3 fold less than that of 16 but 
similar to that of 17. 
Replacing the aromatic moiety with aliphatic chains as in 
compounds 20 and 21 completely abolished the activity which 
indicates the importance of the aromatic ring in that position 
for the trypanocidal activity. The π system of the aromatic ring 
may be involved in the interaction site, whereas with aliphatic 
side chains, such interactions don’t exist. Interestingly, the 
introduction of a small hydrophobe such as a methyl group on 
the para position on the phenyl ring of the aromatic sulfonyl 
moiety (compound 19) made little difference to the activity 
(IC50/SI= 3.4 µM/>24) compared to 10. As the mode of action 
and the target of the compounds are not yet known, the role of 
this methyl group cannot be assured, however, it might be 
involved in a hydrophobic interaction within the target site.  
The extension of the ethyl side chain of the other sulfonyl 
group (second changeable moiety) to a propyl group, as in 
compound 22, was also tolerated (IC50/SI= 1.84 µM/>29) with 
no significant difference in the activity compared to 19. 
However, in the case of compound 26, the extra length of this 
substituent was not tolerated. When the p-tolyl group of 22 
was replaced by a thiophene ring (compound 26), the activity 
was completely abolished due to the propyl group compared to 
16 (with an ethyl side chain).  
The para position of the methyl hydrophobe in 22 was 
important for activity as can be indicated by the inactivity of 
compounds 27 (ortho position) and 28 (meta position). The 
relatively good activity of 29 and 31 is moderated by a poor SI 
when compared to 10 or 22. The inactivity of 30 (no p-methyl 
group) also gives indications about the importance of the para 
position. Figure 4 shows the SAR for this series of bis-
sulfonamides. 
Addition of the hydrophobic methyl groups on either the 
ethyl side chain or on the aromatic sulfonyl moieties seemed to 
act as a tuner for the activity. Compound 26 was completely 
inactive whereas compound 25 showed similar activity and 
selectivity (IC50/SI= 3.5 µM/>24) compared to the lead 10. 
Increasing the bulkiness of compound 22 to 23 (replacing the 
small methyl hydrophobe with the more bulky isopropyl 
group) resulted in a similar activity profile but increased 
toxicity (IC50/SI= 1.71 µM/>8). Further increases in the 
bulkiness by replacing the isopropyl in 23 by a phenyl ring 
(24) decreased the activity (IC50/SI= 5.7 µM/>16) by 3 fold 
compared to 23. This difference could be attributed to a size 
effect. This also confirms that the π system of the aromatic 
ring (directly attached to the sulfonamide group) might be 
involved in the activity. 
When the aliphatic sulfonyl side chain (sulfonyl group 
attached to the tetrahydroquinoline N) was replaced with 
aromatic ring, the activity was either completely abolished as 
in case of compound 32 or toxicity was increased as in 
compounds 33-35. Interestingly, compound 33 carrying the 
para methyl group was the best in this series (IC50/SI= 3.1 
µM/>2), confirming the importance of the para position on 
this aromatic moiety. The aliphatic sulfonyl groups directly 
attached to the tetrahydroquinoline ring is important for 
activity rather than an aromatic replacement. 
An initial structure-activity relationships (SAR) model can 
be generated from this information (Figure 4). Treating the 
tetrahydroisoquinoline unit as a scaffold, toxicity is minimized 
if the sulfonamide (blue) is aliphatic with the hydrophobicity 
tolerated up to 3 methylene units. Larger moieties reduce the 
activity. In contrast, the 2nd sulfonamide unit (red) must be 
aromatic, indicating that the π‐electrons  are  likely  to  be 
significant. Aliphatic substituents abolish activity. 
 
Figure 4. Structure-activity relationships for the bis-sulfonamides 
The activity is maximized when this aromatic unit is 
substituted in the para position. The substituent is best as a 
small hydrophobic unit with a positive inductive effect. 
This study revealed a new structural class of T. brucei 
inhibitors with a good selectivity index, suitable for further 
investigations. Close adherence to drug-like properties 
throughout the study kept the mwt of synthesized derivatives 
low and ClogP were used as a guide to pharmacokinetic 
properties to maintain. Initial SAR studies confirm the initial 
hit compound and enabled basic design principles to be 
observed. Further optimization of this sulfonamide series is 
possible, in particular the para position of the terminal aryl 
sulfonamide group, and further studies in this direction will be 
forthcoming. Therefore, the discovery of the bis-sulfonamides 
as a novel class of antiparasitic agents offers a new medicinal 
chemistry opportunity for targeting T. brucei spp.  
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